Plasma fluorescent oxidation products: independent predictors of coronary heart disease in men.

Plasma fluorescent oxidation products: independent predictors of coronary heart disease in men. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Plasma fluorescent oxidation products: independent predictors of coronary heart disease in men. Abstract Text:

Tianying Wu,Nader Rifai,Walter C Willett,Eric B Rimm,

Fluorescent oxidation products in plasma are stable with routine blood collection methods and reflect oxidation in food, animals, and in vitro. Whether plasma fluorescent oxidation products predict future coronary heart disease has not been established. Among US men without cardiovascular disease who provided blood specimens in 1994 in the Health Professionals Follow-up Study, the authors confirmed 266 incident nonfatal myocardial infarction or fatal coronary heart disease endpoints during 6 years of follow-up. Using a nested case-control design, they measured baseline levels of fluorescent oxidation products. Each case was matched with two controls according to age, smoking status, and time of blood draw. The relative risk of coronary heart disease between extreme quintiles was 1.83 (95% confidence interval: 1.07, 3.13; p for trend = 0.005) in the multivariate analysis controlling for other cardiovascular risk factors and traditional lipid markers. Further adjustment for C-reactive protein and glycated hemoglobin A(1c) did not materially attenuate this association. The multivariate-adjusted relative risk between extreme quintiles was 3.36 (95% confidence interval: 1.33, 8.48; p for trend = 0.005) when the analysis was restricted to men who had fasted for more than 10 hours before blood draw. The authors found that plasma fluorescent oxidation products significantly and independently predicted coronary heart disease incidence among men without previous cardiovascular events.

Plasma fluorescent oxidation products: independent predictors of coronary heart disease in men. Publishing Authors By Initials

T Wu,N Rifai,WC Willett,EB Rimm,

For similar geographic locations: americas: north america: united states research abstracts see: geographic locations: americas: north america: united states research

PUBMED ID PMID:

MEDLINE DATE:

Plasma fluorescent oxidation products: independent predictors of coronary heart disease in men. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: American journal of epidemiology

VOLUME: 166

Page Numbers: 544-51

Journal Abbreviation: Am. J. Epidemiol.

ISSN: 0002-9262

DAY: 5

MONTH: 07

YEAR: 2007

Plasma fluorescent oxidation products: independent predictors of coronary heart disease in men. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7910653

Plasma fluorescent oxidation products: independent predictors of coronary heart disease in men. Keywords Mesh Terms:

KEYWORDS: United States

MESH TERMS: epidemiology

Chemical & Substance for Abstract: Plasma fluorescent oxidation products: independent predictors of coronary heart disease in men. Information

Substance Name: C-Reactive Protein

Registry Number: 9007-41-4

Grant and Affiliation Information for Plasma fluorescent oxidation products: independent predictors of coronary heart disease in men.

AFFILIATION: Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA. hptwu@channing.harvard.edu

Country: United States

AGENCY: United States NHLBI

GRANT: HL35464

ACRONYM: HL

MEDLINETA: Am J Epidemiol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Plasma fluorescent oxidation products: independent predictors of coronary heart disease in men Related Publications

• 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study.
• Adiponectin and risk of acute coronary syndromes: defining the obesity phenotype.
• Alcohol consumption patterns and HbA1c, C-peptide and insulin concentrations in men.
• Alcohol consumption, TaqIB polymorphism of cholesteryl ester transfer protein, high-density lipoprotein cholesterol, and risk of coronary heart disease in men and women.
• An unusual presentation of Best's disease.
• C-Reactive Protein (CRP) Gene Polymorphisms, CRP Levels, and Risk of Incident Coronary Heart Disease in Two Nested Case-Control Studies.
• Classification of breast cancer using genetic algorithms and tissue microarrays.
• Common genetic variation in the ATP-binding cassette transporter A1, plasma lipids, and risk of coronary heart disease.
• Complement factor H (Y402H) polymorphism and risk of coronary heart disease in US men and women.
• Drinking frequency and quantity and risk of suicide among men.
• Effects of 5-fluorouracil (NSC-19893) in 389 patients with cancer. Eastern Clinical Drug Evaluation Program.
• Effects of 6-mercaptopurine (NSC-755) in 290 patients with advanced cancer. Eastern Clinical Drug Evaluation Program.
• Effects of chlorambucil (NSC-3088) in 374 patients with advanced cancer. Eastern Clinical Drug Evualuation Program.
• Effects of lymphotoxin-alpha gene and galectin-2 gene polymorphisms on inflammatory biomarkers, cellular adhesion molecules and risk of coronary heart disease.
• Effects of meturedepa (NSC-51325) in 233 patients with advanced cancer. Eastern Clinical Drug Evaluation Program.
• Effects of mitomycin c (NSC-26980) in 346 patients with advanced cancer. Eastern Clinical Drug Evaluation Program.
• Electronic computers for evaluation of clinical data. I. Man versus machine.
• Fine-needle aspiration of follicular adenoma versus parathyroid adenoma: the utility of multispectral imaging in differentiating lesions with subtle cytomorphologic differences.
• Inflammation, the metabolic syndrome, and risk of coronary heart disease in women and men.
• Localization and quantitation of expression of the cell motility-related protein thymosin beta15 in human breast tissue.
• Plasma fluorescent oxidation products as potential markers of oxidative stress for epidemiologic studies.
• Plasma fluorescent oxidation products: independent predictors of coronary heart disease in men.
• Quantitative analysis of estrogen receptor heterogeneity in breast cancer.
• Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implicatio
• Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer.
• Single nucleotide polymorphisms at the adiponectin locus and risk of coronary heart disease in men and women.
• Soluble intercellular adhesion molecules, soluble vascular cell adhesion molecules, and risk of coronary heart disease.
• The association between betaine and choline intakes and the plasma concentrations of homocysteine in women.
• Vitamin Intake and Risk of Coronary Disease: Observation versus Intervention.
• Waist to hip ratio as a supplement to body mass index.